Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data

2019 ◽  
Vol 32 (4) ◽  
pp. 576-583 ◽  
Author(s):  
Ashley M. Hopkins ◽  
Madele Van Dyk ◽  
Andrew Rowland ◽  
Michael J. Sorich
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Clinical Trial Data ◽  
Pooled Analysis ◽  
Advanced Melanoma ◽  
Trial Data ◽  
Survival Outcomes ◽  
Melanoma Patients

A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs

CNS Drugs ◽  
2010 ◽  
Vol 24 (12) ◽  
pp. 1055-1068 ◽  
Author(s):  
John-Kenneth Sake ◽  
David Hebert ◽  
Jouko Isojärvi ◽  
Pamela Doty ◽  
Marc De Backer ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Antiepileptic Drugs ◽  
Mechanism Of Action ◽  
Clinical Trial Data ◽  
Pooled Analysis ◽  
Trial Data

scholarly journals 488 The impact of education on novel concepts in metastatic melanoma: triplet therapy

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A524-A524
Author(s):  
Kinjal Parikh ◽  
Sara Fagerlie ◽  
Patrick Kugel ◽  
Richard Caracio ◽  
Ryan Sullivan
Keyword(s):  
Clinical Trial ◽  
Checkpoint Inhibitors ◽  
Panel Discussion ◽  
Clinical Trial Data ◽  
Advanced Melanoma ◽  
Trial Data ◽  
Educational Activity ◽  
List Type ◽  
The Impact ◽  
Post Assessment

BackgroundAdvanced melanoma treatment selection is guided by BRAF-mutation status and patient and disease-specific factors. Historically, oncologists decided between targeted therapy or immune checkpoint inhibitors (ICI). However, given the differences in onset of activity, response durability, and adverse events combination BRAF/MEK inhibitors and ICI (triplet therapy) are being evaluated to optimize outcomes. With several trials due to report, oncologists need education to stay up-to-date on the available data and contextualize this potential treatment option.MethodsAn online continuing education (CME) activity consisting of a multi-media 30-minute video panel discussion explored the rationale, available clinical trial data, and future directions of triplet therapy for the treatment of advanced BRAF-mutated melanoma. Educational effect was assessed using a repeated pairs pre-assessment/post-assessment study design and compared the pre- and post-assessment responses. A chi-square test was used to identify differences between pre- and post-assessment responses. Effect size was calculated using Cramer’s V test by determining the strength of the association between the activity and the outcomes (V = 0.16–0.26 is considerable and V > 0.26 is extensive). P values were calculated and those < 0.05 were considered statistically significant. Data from oncologist participants were collected between 12/23/2019 through 2/26/20.ResultsParticipation in education resulted in statistically significant improvements and noticeable educational effect for oncologists (n=49; p < 0.05, V =0.136). • 39% of pre-assessment questions were correctly answered increasing to 52% post-assessment • 15% of oncologists had a measurable improvement in confidence regarding the rationale for use of triplet therapy in advanced melanoma• Significant improvement in knowledge regarding clinical trial data in triplet therapy was observed (35% vs. 55%; p < 0.05, V = 0.205)ConclusionsThis online, interactive, expert-led, CME-certified educational activity resulted in significant gains in oncologist knowledge and confidence regarding triplet therapy in the management of melanoma. These results demonstrate the effectiveness of on-demand education but also highlight an ongoing need for education on this topic as further data becomes available.AcknowledgementsThis educational initiative was supported through educational grants from Novartis Pharmaceuticals Corporation and GenentechReferenceSullivan RJ, Salama AKS. Managing Melanoma: Emerging Concepts of Triplet Therapy. https://www.medscape.org/viewarticle/923003

scholarly journals 2019–2020 Drug Updates in Hematologic Malignancies

2021 ◽  
Vol 12 (3) ◽  
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Clinical Trial Data ◽  
Hematologic Malignancies ◽  
Trial Data ◽  
Pivotal Clinical Trial

During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed pivotal clinical trial data, and covered the adverse events of these hematologic medications.

scholarly journals 2019–2020 Drug Updates in Solid Tumors

2021 ◽  
Vol 12 (3) ◽  
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Solid Tumors ◽  
Clinical Trial Data ◽  
Signs And Symptoms ◽  
Trial Data ◽  
Advanced Practice ◽  
Practice Setting ◽  
Life Threatening

During JADPRO Live Virtual 2020, Kirollos S. Hanna, PharmD, BCPS, BCOP, updated the audience on the pharmacology, new indications, and the clinical trial data of novel medications as well as expanded indications in solid tumors. Dr. Hanna also discussed signs and symptoms of potential serious and life-threatening adverse events, and how new therapeutic entities will impact the advanced practice setting.

scholarly journals Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data

2010 ◽  
Vol 43 (3) ◽  
pp. 376-384 ◽  
Author(s):  
Xinan Yang ◽  
Yong Huang ◽  
Matthew Crowson ◽  
Jianrong Li ◽  
Michael L. Maitland ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Kinase Inhibition
Sign in / Sign up

Export Citation Format

Share Document